UCB Acquires Zogenix to Bolster its Epilepsy Portfolio
By Ashish Tripathi
Pharma Deals Review: Vol 2022 Issue 2 (Table of Contents)
Published: 1 Feb-2022
DOI: 10.3833/pdr.v2022.i2.2667 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a bid to strengthen its epilepsy pipeline, UCB has agreed to acquire rare disease drug developer, Zogenix, for US$26 per share which represents a total transaction value of US$1...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS